188 related articles for article (PubMed ID: 31373792)
1. A Glycoconjugated SIRT2 Inhibitor with Aqueous Solubility Allows Structure-Based Design of SIRT2 Inhibitors.
Hong JY; Price IR; Bai JJ; Lin H
ACS Chem Biol; 2019 Aug; 14(8):1802-1810. PubMed ID: 31373792
[TBL] [Abstract][Full Text] [Related]
2. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
[TBL] [Abstract][Full Text] [Related]
3. Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities.
Spiegelman NA; Price IR; Jing H; Wang M; Yang M; Cao J; Hong JY; Zhang X; Aramsangtienchai P; Sadhukhan S; Lin H
ChemMedChem; 2018 Sep; 13(18):1890-1894. PubMed ID: 30058233
[TBL] [Abstract][Full Text] [Related]
4. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
Yagci S; Gozelle M; Kaya SG; Ozkan Y; Aksel AB; Bakar-Ates F; Dundar Y; Eren G
Bioorg Med Chem; 2021 Jan; 30():115961. PubMed ID: 33360574
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T
Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955
[TBL] [Abstract][Full Text] [Related]
6. Assessment of SIRT2 Inhibitors in Mouse Models of Cancer.
Negrón Abril YL; Fernández I; Weiss RS
Methods Mol Biol; 2019; 1983():151-171. PubMed ID: 31087297
[TBL] [Abstract][Full Text] [Related]
7. Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition.
Radwan MO; Ciftci HI; Ali TFS; Koga R; Tateishi H; Nakata A; Ito A; Yoshida M; Fujita M; Otsuka M
Bioorg Med Chem Lett; 2020 Oct; 30(19):127458. PubMed ID: 32755678
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors.
Eren G; Bruno A; Guntekin-Ergun S; Cetin-Atalay R; Ozgencil F; Ozkan Y; Gozelle M; Kaya SG; Costantino G
J Mol Graph Model; 2019 Jun; 89():60-73. PubMed ID: 30870650
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Advantage of SIRT2-Selective versus pan-SIRT1-3 Inhibitors.
Hong JY; Fernandez I; Anmangandla A; Lu X; Bai JJ; Lin H
ACS Chem Biol; 2021 Jul; 16(7):1266-1275. PubMed ID: 34139124
[TBL] [Abstract][Full Text] [Related]
10. Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis.
Huang S; Song C; Wang X; Zhang G; Wang Y; Jiang X; Sun Q; Huang L; Xiang R; Hu Y; Li L; Yang S
J Chem Inf Model; 2017 Apr; 57(4):669-679. PubMed ID: 28301150
[TBL] [Abstract][Full Text] [Related]
11. Discovery of (5-Phenylfuran-2-yl)methanamine Derivatives as New Human Sirtuin 2 Inhibitors.
Wang L; Li C; Chen W; Song C; Zhang X; Yang F; Wang C; Zhang Y; Qian S; Wang Z; Yang L
Molecules; 2019 Jul; 24(15):. PubMed ID: 31357491
[TBL] [Abstract][Full Text] [Related]
12. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
Galli U; Mesenzani O; Coppo C; Sorba G; Canonico PL; Tron GC; Genazzani AA
Eur J Med Chem; 2012 Sep; 55():58-66. PubMed ID: 22835719
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Selective SIRT2 Inhibitor and Its Anti-breast Cancer Activity.
Shah AA; Ito A; Nakata A; Yoshida M
Biol Pharm Bull; 2016; 39(10):1739-1742. PubMed ID: 27725455
[TBL] [Abstract][Full Text] [Related]
14. Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines.
Kozako T; Mellini P; Ohsugi T; Aikawa A; Uchida YI; Honda SI; Suzuki T
BMC Cancer; 2018 Aug; 18(1):791. PubMed ID: 30081901
[TBL] [Abstract][Full Text] [Related]
15. HaloTag-Targeted Sirtuin-Rearranging Ligand (SirReal) for the Development of Proteolysis-Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)*.
Schiedel M; Lehotzky A; Szunyogh S; Oláh J; Hammelmann S; Wössner N; Robaa D; Einsle O; Sippl W; Ovádi J; Jung M
Chembiochem; 2020 Dec; 21(23):3371-3376. PubMed ID: 32672888
[TBL] [Abstract][Full Text] [Related]
16. Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structure-Activity Relationship, X-ray Crystal Structure, and Anticancer Activity.
Moniot S; Forgione M; Lucidi A; Hailu GS; Nebbioso A; Carafa V; Baratta F; Altucci L; Giacché N; Passeri D; Pellicciari R; Mai A; Steegborn C; Rotili D
J Med Chem; 2017 Mar; 60(6):2344-2360. PubMed ID: 28240897
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, in-vitro evaluation and molecular docking studies of novel indole derivatives as inhibitors of SIRT1 and SIRT2.
Manjula R; Gokhale N; Unni S; Deshmukh P; Reddyrajula R; Srinivas Bharath MM; Dalimba U; Padmanabhan B
Bioorg Chem; 2019 Nov; 92():103281. PubMed ID: 31561106
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of certain benzothieno[3,2-d]pyrimidine derivatives as a selective SIRT2 inhibitors.
Khalil NA; Ahmed EM; Zaher AF; El-Zoghbi MS; Sobh EA
Eur J Med Chem; 2020 Feb; 187():111926. PubMed ID: 31812033
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
Yang L; Ma X; Yuan C; He Y; Li L; Fang S; Xia W; He T; Qian S; Xu Z; Li G; Wang Z
Eur J Med Chem; 2017 Jul; 134():230-241. PubMed ID: 28415012
[TBL] [Abstract][Full Text] [Related]
20. Hit evaluation results in 5-benzyl-1,3,4-thiadiazole-2-carboxamide based SIRT2-selective inhibitor with improved affinity and selectivity.
Gozelle M; Kaya SG; Aksel AB; Ozkan E; Bakar-Ates F; Ozkan Y; Eren G
Bioorg Chem; 2022 Jun; 123():105746. PubMed ID: 35358824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
